Scientific Advisory Board

We are very fortunate to have a specialized Scientific Advisory Board (SAB) which combined has: a) published more than 500 peer-reviewed scientific publications; b) participated in over 50 FDA clinical trials; and c) has invented/brought to market 5 new drugs.

The SAB was chosen based on expertise from basic research to clinical trials, to commercial implementation.  Basic cancer immunology researchers, Dr. Davorka Messmer worked with the discoverer of the dendritic cell, Dr. Ralph Steinman at Rockefeller University, and since has been a prolific researcher identifying many of the key elements which the innate immune system uses in fighting cancer.  Dr. Mehmet Kilinic’s basic research is focused on how cellular stress and viral infections can be used to selectively kill tumors and induce immunity subsequent to infection.

In translational research, Dr. Michael Agadjanyan was one of the original inventors of the DNA vaccine, which is utilized by numerous companies in cancer immunology clinical trials.  Additionally, Dr. Agadjanyan has developed numerous tumor vaccines and immunotherapeutic approaches which are currently being translated into clinical trials.

Dr. Boris Minev was one of the key developers of Melacine, the first tumor vaccine to receive marketing approval in the Western Hemisphere.  Dr. Minev is currently working with viruses that preferentially kill tumor cells, having taken this approach into Phase II oncology trials.

Dr. Thomas Ichim is inventor of a new stem cell, which entered clinical trials and purchased by the NYSE-traded company, Intrexon.  Additionally Dr. Ichim is inventor on over 50 patents and patent applications related to cancer immunotherapy.  ValloVax, the first cancer blood vessel targeting vaccine, a “second generation” Govallo vaccine was invented by Dr. Ichim.

Dr. Thomas E. Ichim

Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. Dr. Ichim spent over 7 years as the President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Subsequent to the acquisition of Medistem by Intrexon, in a deal worth $26 million, Dr. Ichim was brought on to the parent company in its cell engineering unit as Vice President of Cellular Therapy.

Boris Minev, MD, Ph.D.

Dr. Minev is the Director of Immunotherapy and Translational Oncology at Genelux Corporation and the Head of the Laboratory of Tumor Immunology at UCSD.  Dr. Minev has extensive experience in immuno-oncology, immunotherapy of cancer, T cell biology and enhancement of antigen presentation, as well as in oncolytic immunotherapy of cancer and oncolytic viruses.  He has considerable supervision & management experience, coordinating activities with partners in Immuno-Oncology, Translational Medicine, Clinical Development, Biomarker Discovery and Academic Centers.
Dr. Minev worked on the development of synthetic and recombinant vaccines for melanoma, breast cancer, prostate cancer, and brain tumors. He participated in numerous pre-clinical and translational projects related to the identification of new targets for immunotherapy of cancer, cytotoxic T cell immunity in patients with cancer, as well as on dendritic cell-based and nanotechnology-based vaccine development.  Dr. Minev worked closely on the development of the first tumor vaccine to be approved by a regulatory body (Melacine).

Dr. Minev has served on the Scientific Advisory Board of several biomedical start-up companies, and has been an advisor for Amgen, Johnson & Johnson, Geron Corporation, McKinsey Consulting and Thomson Current Drugs, among others.  In 2010, Dr. Minev joined Genelux Corporation where he is directing several preclinical and translational projects on oncolytic virotherapy, immunotherapy and nanotechnology.

Dr. Michael Agadjanyan

Dr. Agadjanyan is an accomplished immunologist with over 100 peer reviewed publications in the area of cancer vaccines and Alzheimer’s.  Dr. Agadjanyan is Professor at the Institute for Molecular Medicine and Professor at the MIND institute of University of California Irvine.  Dr. Agadjanyan was one of the main inventors of DNA vaccination, which is currently in over 50 clinical trials.  He holds numerous NIH grants and over 20 patents and patent applications.

Dr. Davorka Messmer

Dr. Messmer has authored numerous papers on the biology and therapeutic applications of Dendritic Cells.  Dr. Messmer was as part of the original team that discovered Dendritic Cells, led by 2011 Noble Prize for Physiology or Medicine recipient Dr. Ralph M. Steinman, considered the father of Dendritic Cells. Dr. Messmer participated in this landmark discovery that is now considered one of the fundamental findings in Immunology.

Dr. Mehmet Okyay Kilinc

Dr. Kilinc is the Assistant Director of Immunotherapy and Translational Oncology at Genelux Corporation.  Dr. Kilinc has extensive experience in immuno-oncology, immunotherapy of cancer, Macrophage biology and characterization of Myeloid Derived Suppressor cells (MDSCs), as well as in oncolytic immunotherapy of cancer and oncolytic viruses.

He has received grants and worked on nanoparticulation, immune-stimulatory cytokines, co-stimulatory molecules and published extensively in prestigious journals such as Cancer Research and Journal of Immunology. He gained considerable supervision & management experience by coordinating of research activities with academia and partners in Immuno-Oncology and Translational Medicine in the last 15 years.

In 2012, Dr. Kilinc joined Genelux Corporation where he is directing several preclinical and translational projects on oncolytic virotherapy, immunotherapy and nanotechnology.